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Background: Chronic cocaine consumption is associated with a decrease in mesolim-
bic dopamine transmission that maintains drug intake. transcranial magnetic stimulation 
(TMS) is gaining reliability, a useful therapeutic tool in drug addiction, since it can modu-
late cortico-limbic activity resulting in reduction of drug craving.
aims: In the present study, we investigated the therapeutic effect of bilateral TMS of 
prefrontal cortex (PFC) in reducing cocaine intake, in a sample of treatment-seeking 
patients with current cocaine use disorder (DSM-V).
Methods: Ten cocaine addicts (DSM-V) were randomly assigned to the active or sham 
stimulation protocol in a double-blind experimental design. Twelve repetitive TMS (rTMS) 
sessions were administered three times a week for 4 weeks at 100% of motor threshold, 
over bilateral PFC. Cocaine intake (ng/mg) was assessed by hair analysis at baseline 
(before treatment, T0), after 1 month (end of treatment, T1), 3 (T2), and 6 (T3) months 
later. All subjects received psychological support weekly.
results: The two-way ANOVA for repeated measures did not show a significant effect 
of the interaction between time and treatment (F4,32 = 0.35; p = 0.87). Despite that result 
indicated no difference in the effect of the two conditions (active vs. sham) along time, 
a decreasing trend in cocaine consumption in active TMS group (F3,23 = 3.42; p = 0.04) 
vs. sham (F3,15 = 1.88; p = 0.20) was observed when we performed exploratory analysis 
with time as factor. Indeed, Post hoc comparisons showed a significant reduction in the 
amount of cocaine detected from the onset to 3 months later (T0–T2; p = 0.02) and to 
the end of treatment (T0–T3; p = 0.01) in addicts from the active group.
conclusion: Bilateral rTMS of PFC at 10 Hz did not show a significant effect on cocaine 
intake compared to sham. However, a long-term reduction on cocaine intake in active 
TMS-treated patients was observed when we considered the time as factor. Further 
studies are required to confirm these encouraging but preliminary findings, in order to 
consolidate rTMS as a valid tool to treat cocaine addiction.
Keywords: cocaine use disorder, dopamine, PFc, rTMs
2Bolloni et al. rTMS and Cocaine Intake
Frontiers in Psychiatry | www.frontiersin.org August 2016 | Volume 7 | Article 133
inTrODUcTiOn
Substance use disorders (SUD) represent a major public health 
concern in the western world, with about 27.7 million young 
adult users in the last year (1). A general consensus has emerged 
on drug addiction as a substance-induced, aberrant form of neu-
ral plasticity (2–5). At the neurotransmitter level, dopamine (DA) 
plays a key role in the neurobiological mechanisms underlying 
cocaine use disorders (CUD) (6, 7). Indeed, preclinical studies 
in rodents have shown a profound reduction in DA-ergic activity 
in cocaine-withdrawn rats and a resulting decrease of DA release 
in the nucleus accumbens (Nacc) (8). In parallel, human imag-
ing studies have shown a reduction in DA D2 receptors in the 
ventral striatum of detoxified cocaine-dependent subjects (6) and 
a blunted DA release as indexed by a reduction of amphetamine-
induced DA release in the limbic striatum (7).
These observations are the fundamental building blocks of 
the DA hypothesis of drug addiction (2), which ascribes to the 
hypo-functioning DA system, a key role in drug abuse and leads 
to theorize that functional “boosting” of the DA signaling (9) may 
have beneficial effects in reducing drug intake.
In spite of recent significant progress in understanding the 
neurobiology of SUD, therapeutic advances have proceeded at a 
slower pace (10, 11), in particular for CUD.
Among the various interventions available for addiction, 
transcranial magnetic stimulation (TMS) (12) represents a non-
pharmacological tool and a testable opportunity in the treatment 
of CUD (13, 14) given its capability to target and modulate specific 
brain circuits. Previous studies on the therapeutic efficacy of TMS 
on drug addiction have focused on the evaluation of craving and 
drug intake in nicotine-dependent subjects (15–17), alcoholics 
(18, 19), and cocaine addicts (20–22). Despite the variability of 
the stimulation protocols applied, the clinical studies highlighted 
a significant reduction in different measures of addictive behavior. 
Unfortunately, the relatively small number of studies, substantial 
inter-study heterogeneity, and lack of head-to-head comparison 
studies make it difficult to identify common factors associated 
with beneficial outcomes. Moreover, discrepancies in the geom-
etry of the magnetic field generated by standard figure-of-eight 
coil and therefore in the brain area targeted by the stimulation, 
may account for the transient effects observed in previous studies 
(22, 23), Recently, a novel probe called H-coil has shown more 
consistent and prolonged effects, presumably due to its ability to 
stimulate the subcortical regions of the brain that are involved 
in the neuropathology of addiction (23–27). Specifically, the 
H-coil can stimulate fronto-striatal circuits that govern cognitive 
control through the efferent projections from pyramidal neurons 
in the PFC to the DA-containing midbrain neurons and other 
subcortical areas. Given these previous findings, we sought to 
investigate the effect of bilateral rTMS of PFC on cocaine intake 
in treatment-seeking subjects affected by CUD and diagnosed 
according to DSM-V criteria (28).
MaTerials anD MeThODs
The study was conducted at the “National Health Service for 
Addiction” of the “Health’s House 1” in Marsciano (A.S.L. No 1 
Umbria, Perugia, Italy). All the procedures were conformed to 
the Good Clinical Practice. The Ethics Committee’s approval 
was received on 16th December 2010. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki 
(Ethics Committee’s Registration n. 1695/10).
Participants
Patient enrollment was conducted from November 2011 to 
November 2014. All the subjects were seeking outpatient treat-
ment for CUD according to DSM-V criteria (28). The inclusion 
criteria were: age between 18 and 65 years; an average cocaine 
consumption during the 4 weeks before screening of 2 days/week 
for a total minimum consumption ranging from 0.5 to 20 ng/mg 
of cocaine amount at the baseline; able to understand and sign the 
informed consent; being motivated to stop the intake. Exclusion 
criteria were: concurrent SUD (except for tobacco smoking); 
lifetime history or a co-morbidity of psychiatric or neurological 
disorders; chronic medical illness; current use of psychotropic 
medications; medical devices (pace-maker, metal implants, device 
for inflating); family history of epilepsy; pregnancy; involvement 
in other clinical trial; or in a legal action (29, 30). All patients 
signed their written, informed consent.
experimental Procedure
All patients underwent toxicological assessments before treat-
ment (T0), 4 weeks later (end of treatment-T1), and after 3 and 
6  months (follow-up at T2 and T3). We used the hair test as 
indirect measure of drug intake because it provides long-term 
information about drug consumption with higher sensitivity and 
specificity than urine analysis (31–33). Through the analysis, we 
monitored the amount of cocaine, cannabis, and opioids over the 
course of the experiment.
Hair Analysis
Reagents and Chemicals
Solvents were from Merck (Milano, Italy). N-methyl-N- 
trimethylsilyltrifluoroacetamide (MSTFA) was obtained from 
Sigma-Aldrich (Milano, Italy). Cocaine, benzoylecgonine (BEG), 
and their deuterated analogs were obtained from Chemical 
Research 2000 (Rome, Italy).
Procedure
A 50 mg hair sample was taken close to the scalp near the posterior 
vertex. All hair samples were analyzed using a fully validated 
method (34). Briefly, the hair samples were washed, cut accurately, 
dried, and spiked with deuterated internal standards. The samples 
were hydrolyzed with 1 ml of 0.1M HCl overnight at 40°C. After 
liquid/liquid extraction (2  ×  5  ml chloroform/hexane/isopro-
panol 50:17:33 v/v/v at pH 8.0) and derivatization with 50 ml of 
MSTFA (70°C, 30 min), 1 μl of the aliquot was submitted to gas 
chromatography/mass spectrometer (Thermo Fisher Scientific, 
Milano, Italy) analysis in selected ion monitoring mode. Ion 
monitoring parameters were: cocaine (82, 182, 303), cocaine D3 
(85, 185, 306), BEG TMS (82, 240, 361), and BEG D3 TMS (85, 
243, 364). The target ions used for quantification are underlined. 
Standard calibration curves were prepared from blank hair forti-
fied with standard solutions. Calibration lines were checked for 
TaBle 1 | Demographic characteristics at baseline (M ± sD and ranges).
rTMs group (n = 10) control group (n = 8)
Gender (M/F) 9/1 7/1
Age 33.9 ± 6.5 (27–48) 32.4 ± 10.6 (23–50)
Education (years) 11 ± 3.5 (8–13) 11.75 ± 2.31 (8–13)
Employed (yes/no) 7/3 4/4
Duration of cocaine 
dependence (years)
12.3 ± 5.7 9.1 ± 6.1
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linearity using the least squares regression method. Adequate 
linearity was observed for all compounds with a correlation 
coefficient (R2) above 0.99. Calculated limits of detection (LOD, 
S/N ≥3) and limits of quantification (LOQ, S/N ≥5) were 0.01 
and of 0.02 ng/mg, respectively, for each compound. As recom-
mended by Society of Hair Testing guidelines (35), we applied 
the 0.50 ng/mg cutoff for cocaine and the 0.05 ng/mg cutoff for 
BEG. Precision (expressed as percent variation coefficient, CV%) 
and accuracy (expressed as bias%) were assessed by intraday and 
interday analyses and were less than 20%.
TMs Device
We used the H1-coil TMS device (Brainsway Ltd., Jerusalem, 
Israel) (23, 36). This technology is composed by a power genera-
tor equipped with a cooling system connected by a mechanic arm 
to a plastic helmet in which is embedded the coil. This device 
is able to produce both sham and active stimulation by using a 
magnetic card linked to a magnetic reader situated near the touch 
screen monitor where the parameters of stimulation can be set. 
The activation of the sham coil mimics the acoustic sounds of 
the “active” one without inducing magnetic fields or discomfort 
for the subject. In this way, each patient received the stimulation 
protocol based on the randomized card assigned (37). During the 
stimulation session, the subject was instructed to sit below the 
helmet, which was located by the experimenter upon the scalp in 
order to stimulate the prefrontal cortex (PFC) bilaterally.
rTMS Protocol
After the recruitment phase, the subjects were randomly 
assigned to active (10  Hz) or sham stimulation protocol in a 
double-blind fashion. All subjects received 3 stimulations per 
week along 4 weeks, for a total amount of 12 stimulations. The 
intensity of stimulation was set at 100% of individual resting 
motor threshold, defined as the lowest intensity needed to obtain 
5/10 evoked motor potentials (MEP) greater than 50 μV from the 
abductor pollicis brevis (APB) of the right hand. We stimulated 
PFC bilaterally at 10  Hz frequency that is considered able to 
enhance the neural response (13, 38). Each stimulation included 
20 trains of 50 pulses each with 15 s of inter-stimulus between 
trains. Each train duration was 5 s long (10 pulses/s) for a total 
amount of 1000 pulses. The sham protocol was settled with the 
same parameters without delivering any pulses. Each session 
lasted about 10 min.
statistics
Multiple independent samples Student’s t-test was used to 
compare demographic features, duration of dependence, and 
toxicological data between the two experimental groups at 
baseline. Two-way and one-way Analysis of Variance (ANOVA) 
for repeated measures was used to evaluate the effects of rTMS 
on cocaine intake between and within groups over the time line 
considered. We therefore applied a post hoc comparison analysis 
between T0 and each subsequent time points (T1, T2, and T3). 
p < 0.05 was considered statistically significant. We normalized 
the toxicological data in order to have a common baseline starting 




We recruited 18 subjects affected by CUD (DSM-V), 16 males, 
and 2 females matched for age, education, and duration of addic-
tion (Table 1).
We did not observe any discomfort in the subjects exposed to 
the treatment except for a patient who suffered from a mild head-
ache after receiving active stimulation. Three subjects from the 
sham group (37%) and one subject from the active group (10%) 
abandoned the study before ending the 12 sessions of stimulation 
(four dropouts). Four more subjects were excluded because of 
the extremely high amount of cocaine measured at T0 that was 
abundantly out of accepted range (four outliers). Two subjects 
out of four (50%) from the sham group relapsed three times after 
the treatment, while two subjects out of six (33%) from the active 
group reported one relapse after 6 months from the treatment. 
At the end of the study, 10 cocaine addicts were admitted to the 
statistics analysis, 6 patients from the active group [1 female, 5 
males; average age 35 years; average duration of cocaine depend-
ency 13  years; average cocaine intake (T0) 7.75  ng/mg], and 4 
patients from the sham group [1 female; 3 males; average age 
34.5 years; average duration of cocaine dependency 11.75 years; 
average cocaine intake (T0) 6.53 ng/mg].
Toxicological Data
All subjects resulted positive for cocaine and negative for opioid 
and cannabis at the hair test analysis at the baseline (T0). The 
hair samples were collected for each group until 6 months after 
the treatment. The two-way ANOVA for repeated measures 
was performed in order to highlight differences between the 
active stimulation effect and the sham over time; no significant 
effect resulted in the interaction between time and treatment 
(F4,32 =  0.35; p =  0.84), which indicated no difference in the 
effect of the two experimental condition (active vs. sham) on 
cocaine intake (Table  2). However considering the paucity of 
the studies available, we performed exploratory analysis, which 
indicated a significant reduction in cocaine intake between T0 
and T2 (t = 3.30; p = 0.02) and T0–T3 (t = 3.72; p = 0.01) time 
in the active TMS group as highlighted by Bonferroni correc-
tion (Figure  1). Moreover, the one-way ANOVA for repeated 
measures with time as factor conducted to explore in depth the 
toxicological data within groups showed a significant reduction 
on cocaine intake in the active group (F3,23 = 3.42; p = 0.04) and 
not in the sham (F3,15 =  1.88; p =  0.20). Post hoc comparison 
FigUre 1 | Depicts the unitary cocaine amount in the two experimental groups along the time line considered from the baseline (T0) till 6 months 
later (T3). Note that only in the active group (10 Hz) there is a significant reduction in the unitary cocaine amount as indexed by T0–T2 (*p = 0.02) and T0–T3 
(**p = 0.01) comparison over the time line.













Interaction 0.2462 4 0.06 F4,32 = 0.35 0.84
Time 3.87 4 0.97 F4,32 = 5.54 0.001**
Column factor 0.33 1 0.33 F1,8 = 0.29 0.60
Subjects (matching) 9.04 8 1.13 F8,32 = 6.46 <0.00
Residual 5.59 32 0.17
The table shows the main effect of “Time” (**p = 0.001). The post hoc comparison 
reveals a consisting reduction in the cocaine amount only in the active group as 
demonstrates by the T0–T2 (p = 0.02) and T0–T3 (p = 0.01) index.
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group in a double-blind manner to minimize potential bias, over 
a 6-month long observation. Our data did not show a significant 
effect of the interaction between treatment and time, which indi-
cated that the two interventions did not differ in the effects on 
cocaine intake, as shown by the two-way ANOVA. However, the 
paucity of the sample can play a role in the result of the statistical 
analysis and it is not improbable that the enlargement of the sam-
ple would turn the decreasing trend in cocaine intake observed 
in the active group vs. sham into a statistical significance. Indeed, 
when we performed exploratory analysis, we found a long-lasting 
decreasing on cocaine intake only in the active group (T0–T2; 
T0–T3) and not in the sham. The significant reduction in cocaine 
intake along time observed in the active group is not associated 
to a significant short-term difference (T1–T2), likely because of 
the intrinsic characteristics of the hair analysis. Indeed, this test is 
used to determine the history and severity of an individual’s drug 
use, and it has been shown to become negative at least 3 months 
after the last intake. The rationale of its utilization in this study 
is based on the evidence that it provides long-term information 
about cocaine assumption, with higher sensitivity and specificity, 
and in a wider surveillance window than urine test (40–42). The 
possibility of a “false negative” effect played by the limited number 
of patients seems to be unlikely, although it cannot be completely 
ruled out. Notably, a lower rate of dropouts was observed in the 
active group (10%) compared to sham (37%): this could be due 
(Duncan Test) showed a significant difference in cocaine amount 
at T0 compared to T3 (p < 0.05) in the active group. 
DiscUssiOn
In the present study, we used high-frequency stimulation (10 Hz) 
with the double objective to hasten neural activity in the bilateral 
PFC, which is known to be hypoactive in addicts (39), and to 
facilitate output toward subcortical areas and provide an activa-
tion of dopaminergic transmission, known to be hypofunctional 
in cocaine addicts as indexed by previous basic and human stud-
ies (9). However, in contrast to previous studies, we tested the 
effects of TMS on cocaine intake both in active and sham control 
5Bolloni et al. rTMS and Cocaine Intake
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to the modulation of specific circuitries related to motivation 
cognition and compliance by the active TMS that strengthens the 
patients’ adherence to the treatment.
In conclusion, the present data are in line with previous stud-
ies that support a beneficial role for rTMS in CUDs (20–22) and 
encourage the investigation on the role of the rTMS parameters in 
modulating the efficacy of stimulation that are matter of intense 
debate (43). Indeed, the frequency/pattern of stimulation seems 
to be a key element in the effects observed. A recent report (20) 
employed 15 Hz twice a day for five consecutive days and obtained 
a reduction in cocaine intake. Likewise, Ceccanti et  al. (18) 
reported a reduction in alcohol intake after 10 sessions of 20 Hz 
TMS in alcoholics. These results prompt clinicians and researchers 
to further investigate on stimulation frequency/pattern as the key 
element to obtain lasting effects that exploit the principles of neu-
ral plasticity (43). Another important issue to comment is on the 
geometry of the coil employed: the common figure-of-eight coil 
(20, 21) delivers a focal unilateral (asymmetric) stimulation site 
whereas the novel design of H1-coil (37) delivers bilateral simul-
taneous stimuli that can modulate prefrontal cortical areas that 
project into subcortical pathways. Since addiction is whole brain 
pathology with no evidence of lateralization (44, 45), the H-coil 
may represent a more suitable tool for future clinical studies aimed 
at reducing drug intake, especially taking advantage from the ulti-
mate H4-coil. Indeed, bilateral simultaneous TMS application can 
be more efficacious in yielding a robust and bilateral dopaminergic 
“boost” as it has been shown in visual imaging studies (46).
Our results, although preliminary and limited by the very 
small sample available, indicate that bilateral rTMS of PFC may 
induce a long-lasting reduction in cocaine intake in subjects 
diagnosed with CUD according to DSM-V criteria. Future stud-
ies will be aimed at optimizing both the sample and the protocol 
characteristics, in order to contribute to the overall definition of 
the rTMS as a valid tool for the treatment of addiction.
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